A Compassionate Policy Shift for Healthcare Facilities
On Thursday, Delaware Governor Matt Meyer officially signed Senate Bill 226 (SB 226) into law, establishing a highly regulated legal framework for terminally ill patients to use medical cannabis inside hospitals and other healthcare facilities across the state. Sponsored by Senator Marie Pinkney (D), the legislation previously secured unanimous, bipartisan support in both the Delaware Senate and the House of Representatives.
The new policy bridges a critical gap in palliative care by resolving the long-standing conflict between patients’ medical needs and clinical site policies. Historically, medical facilities have explicitly prohibited the administration of medical marijuana due to federal funding and compliance concerns. Set to take effect one year after its enactment, SB 226 offers a legal pathway for patients and their caregivers to safely acquire, securely store, and administer therapeutic cannabis while receiving in-patient care.
Strict Guidelines for In-Hospital Consumption
While the law significantly expands medical cannabis access for the terminally ill, it comes with rigorous administrative and operational guardrails. To minimize disruption and ensure overall patient safety, the legislation strictly prohibits the smoking or vaping of medical cannabis inside any healthcare center. Patients must instead utilize alternative consumption methods, such as tinctures, edibles, or topicals. Furthermore, the right to use medical cannabis under SB 226 explicitly does not extend to patients receiving care in hospital emergency departments.
Healthcare facilities will bear new administrative responsibilities under the law. Hospital officials are required to visually verify a patient’s state-issued medical marijuana registry ID card and formally document the patient’s cannabis use within their clinical records. Additionally, each facility must develop and proactively disseminate comprehensive, site-specific written policies outlining procedures for safe medical cannabis storage and administration.
Federal Protections and Facility Discretion
Because cannabis remains classified as a Schedule I substance at the federal level, hospitals are understandably cautious regarding potential compliance issues with federal agencies. To mitigate this risk, SB 226 grants healthcare facilities the explicit authority to prohibit medical cannabis use if clinicians determine the substance would have an “adverse impact on the medical care and treatment of the patient” or if it is otherwise medically contraindicated.
The legislation also includes a “safe harbor” provision to protect clinical institutions from federal retaliation. A facility may temporarily or permanently suspend permission for inpatient cannabis use if a federal entity—such as the U.S. Department of Justice (DOJ) or the Centers for Medicare and Medicaid Services (CMS)—takes enforcement action or issues formal guidance that expressly prohibits such use.
Delaware’s Evolving Cannabis Landscape
The signing of this hospital access bill comes as Delaware continues to rapidly adapt to a post-prohibition landscape. In August 2025, the state’s Office of the Marijuana Commissioner successfully oversaw the launch of the adult-use recreational market, initially spearheaded by medical marijuana conversion licensees—also known as compassion centers. Since then, state regulators and lawmakers have actively focused on refining cannabis policies, improving medical access, and addressing local zoning disputes as the industry matures.
By integrating medical cannabis into traditional healthcare settings for palliative care, Delaware joins a growing but select group of states prioritizing patient autonomy and compassionate end-of-life treatments. Industry advocates view SB 226 not just as a victory for terminally ill patients, but as a potential pilot model for the broader integration of medical cannabis into traditional healthcare systems nationwide.
